论文部分内容阅读
美《医学世界新闻》第20卷第24期(1979年)第25页报道新奥尔良消息:现正对医生提供一种较好的拟氧气药物,以治疗对标准放射疗法有抗力的肿瘤,因为癌瘤是缺氧的。放射致敏剂之一是Misonidazole,新近在对50例头、颈晚期癌的试验研究中,很有希望。放射科医生认为,Misonidazole仅仅是新强效药中的先躯者,这些药物可使低氧的肿瘤细胞对放射线增加二倍或三倍的敏感性。关于Misonidazole的试验,在美国放射治疗学会上已提及。费城的法兹克斯(John
The United States “Medical World News” Vol. 20 No. 24 (1979) Page 25 Report from New Orleans: It is now providing doctors with a better oxygenation drug to treat tumors that are resistant to standard radiation therapy because Cancer is hypoxic. One of the radiosensitizers is Misonidazole, which is promising in recent 50 pilot studies of head and neck cancer. According to radiologists, Misonidazole is only the forerunner of new powerful drugs that can increase the sensitivity of hypoxic tumor cells to radiation by two or three times. The test on Misonidazole has been mentioned in the American Society of Radiation Therapy. Philadelphia’s Fazkes (John